Happy Holidays to All of You

From our families to yours. We appreciate all of your support throughout the year and hope your holidays are filled with happiness and joy.

Holiday Office Hours

• Friday, December 23: National Office will close at 5 p.m. eastern.
• Monday, December 26: Office closed in observance of Christmas
• Friday, December 30: National Office will close at 5 p.m. eastern.
• Monday, January 2, 2017 - Office closed in observance of New Year's Day
• Tuesday, January 3, 2017: Regular Office Hours 8:30 a.m. to 5 p.m. eastern

If you need assistance or would like to make a holiday gift, please call during office hours. Otherwise, you can donate online through our website 24/7. Please visit national.scleroderma.org/eoy

Give the Gift of Membership

This year, give a gift to someone of an annual membership to the Scleroderma Foundation and support our organization and its important mission to help support, educate and advocate for people living with scleroderma.

For $25 ($35 for international), you will receive:

• A subscription to the award-winning quarterly magazine "Scleroderma Voice", including articles about research advancements, inspiring patient profiles, and Q&A's with some of the leading scleroderma experts from around the globe
• Discounts to attend the National Patient Education Conference
• And other benefits

Learn more about membership benefits and join today >>

What is Chronic Pain?

The American Chronic Pain Association offers answers to some frequently asked questions about ongoing pain and how to manage it. Topics include finding a doctor who specializes in chronic pain, using medications safely, and what to expect from your health care team.

Read more >>

Catalyst for Patients with CTD-PAH

Catalyst is a Phase III clinical study evaluating the safety and efficacy of bardoxolone methyl (an oral medication) for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH). This includes PAH associated with lupus, scleroderma, Sjögren’s syndrome, rheumatoid arthritis, and other connective tissue diseases. Approximately 200 patients will be enrolled at centers in various countries around the world.

Before participating, patients must complete the screening process at one of the study centers. Eligible patients will receive either BARD capsules or placebo capsules and will be instructed to take the capsules once daily for 24 weeks. The study team will follow patients closely and will conduct visits through the duration of participation. The investigational drug, study-related procedures, and doctor visits will be provided. You may receive compensation for your time and travel.

More information >>